Skip to content

Clinical presentation and diagnosis

TL;DR — Leukocoria and strabismus are the dominant presenting signals, but neither is specific; the safety-critical response is prompt dilated examination by an experienced ophthalmic team. Diagnosis is usually clinical under examination under anaesthesia with wide-field documentation, ultrasonography and MRI for optic-nerve, orbital and intracranial assessment. Routine intraocular biopsy is avoided because a transocular tract can breach a confined tumour. Delays should be decomposed into recognition, first-contact, specialist-diagnosis and treatment-start intervals.

Decision-relevant evidence

  • Leukocoria and strabismus dominate presentation, and the sign predicts the stage. Among 4,578 treatment-naive children from 259 centres in 121 countries, curable IRSS stage 0/I/II disease accompanied 94.8% of strabismus and 90.1% of leukocoria presentations but only 66.7% of orbital cellulitis and 33.7% of orbital mass presentations; leukocoria was the commonest sign at every national income level (Yanagihara 2025, PMID 40334716).

  • Registry series show the same signs with different mixes: in 119 Malaysian children (162 eyes) diagnosed 2004–2012, median age at presentation was 22 months, 63.8% were unilateral, and leukocoria (110), strabismus (19) and proptosis (12) were the leading signs, with extraocular extension in more than half of the unilateral eyes taken to enucleation (Subramaniam 2014, PMID 25292078). In 96 Taiwanese children treated 1978–2000, leukocoria appeared in 78.1%, buphthalmos in 35.4%, proptosis in 16.7% and strabismus in 12.5%, and three-year cumulative survival was 64.4% (71.97% unilateral, 40.01% bilateral) (Kao 2002, PMID 12457919).

  • In 1,120 Indian children, mean symptom-to-treatment lag was 4.2 months and parent lag was 44% of it, with diagnosis lag 26% and treatment lag 31%; first consultation with a non-specialist was significantly associated with longer lag (P = 0.001), as were lower socio-economic status (P = 0.006) and greater distance from the treating centre (P = 0.001) (Das 2025, PMID 40719713).

  • Untreated disease has a documented natural history that makes the urgency concrete. Among 44 children who abandoned treatment at diagnosis across 29 Chinese centres, median time from intraocular diagnosis to orbital disease was 13.7 months, orbital disease to metastasis 2.6 months and metastasis to death 2.0 months; 36% died within 12 months, 77% within 24, 95% within 36 and 100% within 48 months (Zhao 2021, PMID 34359552).

  • Diagnosis is clinical and radiological, not histological: examination under anaesthesia with indirect ophthalmoscopy plus imaging is the standard pathway, and transocular biopsy is avoided because of seeding risk (Ademola-Popoola 2019, PMID 31187745; Meel 2024, PMID 38609685).

  • High-resolution MRI is the imaging modality of choice for local and intracranial extension and for follow-up; CT is no longer indicated despite the characteristic calcification, because these children include a large radiosensitive germline-carrier fraction (Schweiger 2022, PMID 35969246; Razek 2011, PMID 21849363).

  • MRI's limits at the staging boundary are documented rather than assumed. In 18 children with histopathological correlation after enucleation, unenhanced T1-weighted imaging correctly excluded extrascleral growth in 16 of 16 cases, but of two abnormal scans only one was confirmed; post-laminar optic-nerve invasion was confirmed in 2 of 3 abnormal gadolinium-enhanced scans and was also present in 1 of 15 cases whose scans were normal. Tumour–vitreous contrast rose 57% after gadolinium on T1 (P = 0.004) (Barkhof 1997, PMID 9166573).

  • Where the diagnosis is genuinely uncertain, aqueous-humour cell-free DNA now substitutes for the biopsy that cannot be done. Targeted sequencing of aqueous cell-free DNA identified a biallelic RB1 deletion and confirmed retinoblastoma in a 13-year-old whose aqueous cytology was inconclusive and whose presentation had been treated as hypertensive anterior uveitis (Kletke 2022, PMID 36326029); conversely, aqueous liquid biopsy with low DNA yield and no retinoblastoma-associated mutations was used to argue against retinoblastoma in an 11-month-old with an intraocular mass, who remained unchanged over six months of observation (Nelson 2025, PMID 40469936). Both are single cases, and a negative result with low yield is weaker evidence than a positive one.

  • Age at presentation separates the laterality groups: mean age at diagnosis was 27.1 months for unilateral and 15.6 months for bilateral disease in the Taiwanese series (PMID 12457919), against a global median of 23.2 months (IQR 11.0–36.5) (PMID 35839812) — the offset that makes an older child with a unilateral mass a different prior from an infant with bilateral tumours.

  • Adult-onset retinoblastoma exists and is a documented diagnostic trap, reported as an uncommon and challenging diagnosis outside the paediatric age range (Verma 2023, PMID 37602177; Sengupta 2016, PMID 27609158).

  • Newborn red-reflex examination for congenital cataract and retinoblastoma is widely accepted despite little evidence of its validity and effectiveness, justified by the severity of both conditions and the outcomes achievable with early detection; the same review finds moderate-certainty evidence of net benefit for vision screening at ages three to five, and uncertain evidence below age three (Jullien 2021, PMID 34496780). The practice that most often makes the diagnosis is therefore the one with the weakest formal evidence base behind it.

Clinical and research frame

Domain Operational meaning Evidence boundary
White pupillary reflex Urgent red-reflex/dilated examination Photographs can reveal but cannot diagnose
New strabismus Prompt ocular assessment Do not assume benign misalignment
EUA Tumour number, size, location, seeds, pressure Creates treatment map
Ultrasound Mass, calcification, detachment No tissue breach
MRI brain/orbits Optic nerve, orbit, intracranial tumour Preferred cross-sectional staging
Needle/incisional biopsy Generally contraindicated Potential extraocular seeding tract

Interpretation rules

  • Keep the child-level endpoints of survival and metastasis separate from the eye-level endpoint of globe salvage.

  • Report initial stage, laterality, heritability, prior treatment and follow-up; otherwise comparisons are not transportable.

  • A retrospective eye series estimates performance in selected eyes; it does not establish superiority over another route.

  • Absence of metastasis in a small series is a safety observation, not proof that risk is zero.

  • Treatment-era effects matter because external-beam radiotherapy, systemic chemotherapy, IAC and intravitreal therapy create different late-risk profiles.

  • Income stratum and access are effect modifiers, not background descriptors (Global Retinoblastoma Study Group 2022, PMID 35839812).

Evidence register

The following records were each retrieved live from PubMed E-utilities on 2026-09-01 and re-fetched live during the independent audit on the same date. Every identifier below resolved, and its author, year, journal and title matched the citation as written. Inclusion records the evidence base for this page; a register entry asserts that the record exists and is on topic, not that it supports a specific effect estimate.

PMID Year Study or review Role in this page
27189421 2015 Retinoblastoma. Topic-resolved source (Dimaras 2015, PMID 27189421)
40719713 2025 Lag time for diagnosis and treatment in 1120 retinoblastoma children: Analysis from InPOG-RB-19-01. Topic-resolved source (Das 2025, PMID 40719713)
21849363 2011 MRI of retinoblastoma. Topic-resolved source (Razek 2011, PMID 21849363)
36326029 2022 A typical anterior retinoblastoma: diagnosis by aqueous humor cell-free DNA analysis. Topic-resolved source (Kletke 2022, PMID 36326029)
35839812 2022 The Global Retinoblastoma Outcome Study: a prospective, cluster-based analysis of 4064 patients from 149 countries. Topic-resolved source (Global 2022, PMID 35839812)
38615905 2024 Recent progress in retinoblastoma: Pathogenesis, presentation, diagnosis and management. Topic-resolved source (Zhou 2024, PMID 38615905)
28620731 2017 Retinoblastoma. Topic-resolved source (Rao 2017, PMID 28620731)
26023180 2016 Retinoblastoma. Topic-resolved source (Ortiz 2016, PMID 26023180)
28695165 2017 Neonatal Retinoblastoma. Topic-resolved source (Kivelä 2017, PMID 28695165)
16934146 2006 Retinoblastoma. Topic-resolved source (Aerts 2006, PMID 16934146)
24100372 2013 Retinoblastoma. Topic-resolved source (Villegas 2013, PMID 24100372)
8199450 1993 Retinoblastoma. Topic-resolved source (Abramson 1993, PMID 8199450)
22337189 2012 Retinoblastoma. Topic-resolved source (Mehta 2012, PMID 22337189)
29049432 2017 Liquid Biopsy in Retinoblastoma. Topic-resolved source (Harbour 2017, PMID 29049432)
33583507 2021 Neonatal Retinoblastoma. Topic-resolved source (Lin 2021, PMID 33583507)
36408154 2022 Retinoblastoma: Review and new insights. Topic-resolved source (Cruz-Gálvez 2022, PMID 36408154)
40731848 2025 Update on Retinoblastoma Therapies. Topic-resolved source (Martínez 2025, PMID 40731848)
32206913 2020 [Retinoblastoma]. Topic-resolved source (Bornfeld 2020, PMID 32206913)
37602177 2023 Adult-onset retinoblastoma: An uncommon and challenging diagnosis. Topic-resolved source (Verma 2023, PMID 37602177)
25473349 2014 Retinoblastoma: An overview. Topic-resolved source (Pandey 2014, PMID 25473349)
29737052 2018 Retinoblastoma for Pediatric Ophthalmologists. Topic-resolved source (AlAli 2018, PMID 29737052)
25940424 2015 Retinoblastoma: diagnosis and management--the UK perspective. Topic-resolved source (Jenkinson 2015, PMID 25940424)
40213298 2025 Retinoblastoma: Aqueous humor liquid biopsy. Topic-resolved source (Sanchez 2025, PMID 40213298)
31187745 2019 Contemporary management of retinoblastoma in the context of a low-resource country. Topic-resolved source (Ademola-Popoola 2019, PMID 31187745)
25292078 2014 Presentation of retinoblastoma patients in Malaysia. Topic-resolved source (Subramaniam 2014, PMID 25292078)
12457919 2002 Retinoblastoma in Taiwan: survival and clinical characteristics 1978-2000. Topic-resolved source (Kao 2002, PMID 12457919)
35734689 2022 An atypical clinical/radiological presentation of Retinoblastoma in a 4-year-old child: A case report & educational lessons from Syria. Topic-resolved source (Hraib 2022, PMID 35734689)
31561918 2019 [Role of CT in diagnosis and monitoring of retinoblastoma in Senegal]. Topic-resolved source (Sow 2019, PMID 31561918)
40469936 2025 Aqueous Humor Liquid Biopsy to Exclude Retinoblastoma for a Child with an Intraocular Mass. Topic-resolved source (Nelson 2025, PMID 40469936)
22414599 2012 Retinoblastoma. Topic-resolved source (Dimaras 2012, PMID 22414599)
29321667 2018 The management of retinoblastoma. Topic-resolved source (Fabian 2018, PMID 29321667)
26969537 2016 Retinoblastoma: An update. Topic-resolved source (Delhiwala 2016, PMID 26969537)
38263682 2024 Global retinoblastoma studies: A review. Topic-resolved source (Vempuluru 2024, PMID 38263682)
40471757 2025 Managing retinoblastoma in 2025. Topic-resolved source (Ramos-Dávila 2025, PMID 40471757)
41645972 2025 Orbital myiasis in neglected orbital retinoblastoma. Topic-resolved source (Panda 2025, PMID 41645972)
40926918 2025 Retinoblastoma in Dandy-Walker Syndrome. Topic-resolved source (Lomi 2025, PMID 40926918)
38609685 2024 Management of Intraocular Retinoblastoma: ICMR Consensus Guidelines. Topic-resolved source (Meel 2024, PMID 38609685)
30350021 2019 Expression profiles and prognostic value of miRNAs in retinoblastoma. Topic-resolved source (Delsin 2019, PMID 30350021)
41280625 2025 Retinoblastoma management in China: clinical challenges. Topic-resolved source (Wang 2025, PMID 41280625)
34359552 2021 Natural History of Untreated Retinoblastoma. Topic-resolved source (Zhao 2021, PMID 34359552)
40334716 2025 Clinical Stage of Retinoblastoma Based on Presenting Signs of 4578 Patients from 121 Countries. Added by audit 2026-09-01 (Yanagihara 2025, PMID 40334716)
35969246 2022 [Imaging of retinoblastoma : Current state-of-the-art and future prospects]. Added by audit 2026-09-01 (Schweiger 2022, PMID 35969246)
9166573 1997 MR imaging in retinoblastoma. Added by audit 2026-09-01 (Barkhof 1997, PMID 9166573)
27609158 2016 Adult onset retinoblastoma. Added by audit 2026-09-01 (Sengupta 2016, PMID 27609158)
34496780 2021 Vision screening in newborns and early childhood. Added by audit 2026-09-01 (Jullien 2021, PMID 34496780)

Source chronology

Era marker PMID What the record contributes
1993 8199450 Retinoblastoma. (Abramson 1993, PMID 8199450)
2002 12457919 Retinoblastoma in Taiwan: survival and clinical characteristics 1978-2000. (Kao 2002, PMID 12457919)
2006 16934146 Retinoblastoma. (Aerts 2006, PMID 16934146)
2011 21849363 MRI of retinoblastoma. (Razek 2011, PMID 21849363)
2012 22337189 Retinoblastoma. (Mehta 2012, PMID 22337189)
2012 22414599 Retinoblastoma. (Dimaras 2012, PMID 22414599)
2013 24100372 Retinoblastoma. (Villegas 2013, PMID 24100372)
2014 25292078 Presentation of retinoblastoma patients in Malaysia. (Subramaniam 2014, PMID 25292078)
2014 25473349 Retinoblastoma: An overview. (Pandey 2014, PMID 25473349)
2015 25940424 Retinoblastoma: diagnosis and management--the UK perspective. (Jenkinson 2015, PMID 25940424)
2015 27189421 Retinoblastoma. (Dimaras 2015, PMID 27189421)
2016 26023180 Retinoblastoma. (Ortiz 2016, PMID 26023180)
2016 26969537 Retinoblastoma: An update. (Delhiwala 2016, PMID 26969537)
2017 28620731 Retinoblastoma. (Rao 2017, PMID 28620731)
2017 28695165 Neonatal Retinoblastoma. (Kivelä 2017, PMID 28695165)

Evidence limitations

  • Most intraocular treatment evidence is observational, single-centre and reported per eye; bilateral eyes within one child are statistically correlated.

  • Classification and treatment changed over time, producing stage migration and confounding by indication.

  • Rare metastatic and late-effect outcomes require multinational cohorts and decades of follow-up.

  • Verification is abstract-level. Every claim on this page was checked against the abstract of the record it cites during the independent audit on 2026-09-01; where an abstract could not support a claim, the claim was removed or restated as an explicit limit. Claims requiring full text beyond the abstract are not made here.

Open questions

  • Which front-line recognition intervention reduces cT4 presentation? The current evidence register defines the design space but does not close the question.

  • Can non-invasive imaging distinguish all major pseudoretinoblastomas safely? The current evidence register defines the design space but does not close the question.

  • How should diagnostic pathways measure and report each lag component? The current evidence register defines the design space but does not close the question.

References

  1. Dimaras H, et al. Retinoblastoma. Nature reviews. Disease primers. 2015;1:15021. PMID 27189421
  2. Das S, et al. Lag time for diagnosis and treatment in 1120 retinoblastoma children: Analysis from InPOG-RB-19-01. Indian journal of ophthalmology. 2025;73:1124-1131. PMID 40719713
  3. Razek AA, et al. MRI of retinoblastoma. The British journal of radiology. 2011;84:775-84. PMID 21849363
  4. Kletke SN, et al. A typical anterior retinoblastoma: diagnosis by aqueous humor cell-free DNA analysis. Ophthalmic genetics. 2022;43:862-865. PMID 36326029
  5. Global Retinoblastoma Study Group. The Global Retinoblastoma Outcome Study: a prospective, cluster-based analysis of 4064 patients from 149 countries. The Lancet. Global health. 2022;10:e1128-e1140. PMID 35839812
  6. Zhou M, et al. Recent progress in retinoblastoma: Pathogenesis, presentation, diagnosis and management. Asia-Pacific journal of ophthalmology (Philadelphia, Pa.). 2024;13:100058. PMID 38615905
  7. Rao R, et al. Retinoblastoma. Indian journal of pediatrics. 2017;84:937-944. PMID 28620731
  8. Ortiz MV, et al. Retinoblastoma. Journal of child neurology. 2016;31:227-36. PMID 26023180
  9. Kivelä TT, et al. Neonatal Retinoblastoma. Asia-Pacific journal of oncology nursing. 2017;4:197-204. PMID 28695165
  10. Aerts I, et al. Retinoblastoma. Orphanet journal of rare diseases. 2006;1:31. PMID 16934146
  11. Villegas VM, et al. Retinoblastoma. Current opinion in ophthalmology. 2013;24:581-8. PMID 24100372
  12. Abramson DH, et al. Retinoblastoma. Optometry clinics : the official publication of the Prentice Society. 1993;3:49-61. PMID 8199450
  13. Mehta M, et al. Retinoblastoma. Singapore medical journal. 2012;53:128-35; quiz 136. PMID 22337189
  14. Harbour JW. Liquid Biopsy in Retinoblastoma. JAMA ophthalmology. 2017;135:1231. PMID 29049432
  15. Lin FY, et al. Neonatal Retinoblastoma. Clinics in perinatology. 2021;48:53-70. PMID 33583507
  16. Cruz-Gálvez CC, et al. Retinoblastoma: Review and new insights. Frontiers in oncology. 2022;12:963780. PMID 36408154
  17. Martínez Arce CA, et al. Update on Retinoblastoma Therapies. Medicina (Kaunas, Lithuania). 2025;61. PMID 40731848
  18. Bornfeld N, et al. [Retinoblastoma]. Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft. 2020;117:389-402. PMID 32206913
  19. Verma R, et al. Adult-onset retinoblastoma: An uncommon and challenging diagnosis. Oman journal of ophthalmology. 2023;16:382-384. PMID 37602177
  20. Pandey AN. Retinoblastoma: An overview. Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society. 2014;28:310-5. PMID 25473349
  21. AlAli A, et al. Retinoblastoma for Pediatric Ophthalmologists. Asia-Pacific journal of ophthalmology (Philadelphia, Pa.). 2018;7:160-168. PMID 29737052
  22. Jenkinson H. Retinoblastoma: diagnosis and management--the UK perspective. Archives of disease in childhood. 2015;100:1070-5. PMID 25940424
  23. Sanchez GM, et al. Retinoblastoma: Aqueous humor liquid biopsy. Taiwan journal of ophthalmology. 2025;15:55-61. PMID 40213298
  24. Ademola-Popoola DS, et al. Contemporary management of retinoblastoma in the context of a low-resource country. The Nigerian postgraduate medical journal. 2019;26:69-79. PMID 31187745
  25. Subramaniam S, et al. Presentation of retinoblastoma patients in Malaysia. Asian Pacific journal of cancer prevention : APJCP. 2014;15:7863-7. PMID 25292078
  26. Kao LY, et al. Retinoblastoma in Taiwan: survival and clinical characteristics 1978-2000. Japanese journal of ophthalmology. 2002;46:577-80. PMID 12457919
  27. Hraib M, et al. An atypical clinical/radiological presentation of Retinoblastoma in a 4-year-old child: A case report & educational lessons from Syria. Annals of medicine and surgery (2012). 2022;78:103830. PMID 35734689
  28. Sow AS, et al. [Role of CT in diagnosis and monitoring of retinoblastoma in Senegal]. Journal francais d'ophtalmologie. 2019;42:1085-1089. PMID 31561918
  29. Nelson AJ, et al. Aqueous Humor Liquid Biopsy to Exclude Retinoblastoma for a Child with an Intraocular Mass. Case reports in ophthalmology. 2025;16:366-371. PMID 40469936
  30. Dimaras H, et al. Retinoblastoma. Lancet (London, England). 2012;379:1436-46. PMID 22414599
  31. Fabian ID, et al. The management of retinoblastoma. Oncogene. 2018;37:1551-1560. PMID 29321667
  32. Delhiwala KS, et al. Retinoblastoma: An update. Seminars in diagnostic pathology. 2016;33:133-40. PMID 26969537
  33. Vempuluru VS, et al. Global retinoblastoma studies: A review. Clinical & experimental ophthalmology. 2024;52:334-354. PMID 38263682
  34. Ramos-Dávila EM, et al. Managing retinoblastoma in 2025. Current opinion in ophthalmology. 2025;36:414-426. PMID 40471757
  35. Panda BB, et al. Orbital myiasis in neglected orbital retinoblastoma. The National medical journal of India. 2025;38:353-354. PMID 41645972
  36. Lomi N, et al. Retinoblastoma in Dandy-Walker Syndrome. Cureus. 2025;17:e89663. PMID 40926918
  37. Meel R, et al. Management of Intraocular Retinoblastoma: ICMR Consensus Guidelines. Indian journal of pediatrics. 2024;91:1166-1176. PMID 38609685
  38. Delsin LEA, et al. Expression profiles and prognostic value of miRNAs in retinoblastoma. Journal of cancer research and clinical oncology. 2019;145:1-10. PMID 30350021
  39. Wang N, et al. Retinoblastoma management in China: clinical challenges. International journal of ophthalmology. 2025;18:2380-2384. PMID 41280625
  40. Zhao J, et al. Natural History of Untreated Retinoblastoma. Cancers. 2021;13. PMID 34359552
  41. Yanagihara RT, et al. Clinical Stage of Retinoblastoma Based on Presenting Signs of 4578 Patients from 121 Countries. Ophthalmology. 2025;132:1045-1053. PMID 40334716
  42. Schweiger B, et al. [Imaging of retinoblastoma : Current state-of-the-art and future prospects]. Radiologie (Heidelberg, Germany). 2022;62:1067-1074. PMID 35969246
  43. Barkhof F, et al. MR imaging in retinoblastoma. European radiology. 1997;7:726-31. PMID 9166573
  44. Sengupta S, et al. Adult onset retinoblastoma. Indian journal of ophthalmology. 2016;64:485-91. PMID 27609158
  45. Jullien S. Vision screening in newborns and early childhood. BMC pediatrics. 2021;21:306. PMID 34496780